
REGENXBIO RGNX
$ 7.16
-1.1%
REGENXBIO Operating Income | RGNX
Operating profit (also called operating income or profit from core activities) is a financial metric that reflects a company's profit from its main operational activities before interest expenses and taxes are taken into account.
FormulaOperating profit = Revenue – Operating expensesFeatures of the metric
- Evaluates business efficiency
Shows how well the company controls its production and administrative costs. - Independent of financial structure
Excludes the impact of debt burden (interest) and taxes, allowing objective comparison of companies. - Main source for growth
High operating profit provides resources for investments, business expansion, and increased competitiveness.
If a company shows strong operating profit, it signals to investors that the core business is operating efficiently, even if net profit is temporarily reduced due to debt or tax burden.
Annual Operating Income REGENXBIO
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -161 M | -233 M | -268 M | -263 M | 160 M | -119 M | -149 M | 88.1 M | -75.9 M | -65.3 M | -23.1 M | -3.68 M | -4.78 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 160 M | -268 M | -86 M |
Quarterly Operating Income REGENXBIO
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -35.5 M | 29.3 M | -83.4 M | -57.6 M | -52.4 M | -63.3 M | 12.1 M | -51.4 M | -62.1 M | -56 M | -63.9 M | -63.9 M | -65 M | -73.1 M | -66.2 M | -57.8 M | -71 M | -62.5 M | -71.5 M | 314 M | -57.3 M | -52.2 M | -44 M | -53.7 M | 14 M | -41.8 M | -37.7 M | -40.3 M | -35.9 M | -36.9 M | -35.9 M | 2.45 M | -22.7 M | 6.35 M | 102 M | -16.6 M | -21.3 M | -15.1 M | -22.9 M | - | -18.7 M | -15 M | -11.3 M | - | -7.35 M | -6.3 M | -3.99 M | - | -1.7 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Quarterly performance
Select metrics to display
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 314 M | -83.4 M | -25.6 M |
Operating Income of other stocks in the Biotechnology industry
| Issuer | Operating Income | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Brickell Biotech
BBI
|
-6.36 M | - | -5.38 % | $ 6.06 M | ||
|
Applied Therapeutics
APLT
|
-104 M | - | - | $ 8.42 M | ||
|
Generation Bio Co.
GBIO
|
-142 M | - | - | $ 344 M | ||
|
Clearside Biomedical
CLSD
|
-28.9 M | - | - | $ 25.3 M | ||
|
Merus N.V.
MRUS
|
-272 M | - | - | $ 5.78 B | ||
|
RAPT Therapeutics
RAPT
|
-136 M | - | - | $ 2.36 B | ||
|
Annexon
ANNX
|
-216 M | $ 3.11 | -8.94 % | $ 482 M | ||
|
Acasti Pharma
ACST
|
-11.1 M | - | 4.01 % | $ 150 M | ||
|
Galapagos NV
GLPG
|
295 M | - | - | $ 1.83 B | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
-418 K | - | -4.36 % | $ 27 M | ||
|
Avenue Therapeutics
ATXI
|
-3.08 M | - | -52.27 % | $ 4.45 M | ||
|
Galmed Pharmaceuticals Ltd.
GLMD
|
-30.2 M | $ 4.63 | 21.05 % | $ 20 M | ||
|
Leap Therapeutics
LPTX
|
-41.1 M | - | 368.57 % | $ 41.9 M | ||
|
Lumos Pharma
LUMO
|
-36.6 M | - | - | $ 35.3 M | ||
|
Gamida Cell Ltd.
GMDA
|
-62.3 M | - | -18.25 % | $ 5.04 M | ||
|
Axcella Health
AXLA
|
-77 M | - | -16.42 % | $ 249 M | ||
|
Metacrine
MTCR
|
-61.1 M | - | - | $ 24.2 M | ||
|
Zealand Pharma A/S
ZEAL
|
-1.05 B | - | 0.52 % | $ 821 M | ||
|
Myovant Sciences Ltd.
MYOV
|
-187 M | - | -0.04 % | $ 2.62 B | ||
|
Bellerophon Therapeutics
BLPH
|
-22.4 M | - | -74.18 % | $ 955 K | ||
|
Idera Pharmaceuticals
IDRA
|
-27.8 M | - | -23.04 % | $ 26.6 M | ||
|
Akero Therapeutics
AKRO
|
-285 M | - | - | $ 3.67 B | ||
|
Verona Pharma plc
VRNA
|
-155 M | - | - | $ 69.7 B | ||
|
Guardion Health Sciences
GHSI
|
-4.34 M | - | -0.31 % | $ 3.64 M | ||
|
Opiant Pharmaceuticals
OPNT
|
5.16 M | - | - | $ 109 M | ||
|
Akouos
AKUS
|
-86.8 M | - | 0.23 % | $ 488 M | ||
|
ImmunoGen
IMGN
|
-221 M | - | - | $ 7.92 B | ||
|
Vascular Biogenics Ltd.
VBLT
|
-14.7 M | - | -8.77 % | $ 12.4 M | ||
|
Cidara Therapeutics
CDTX
|
-176 M | - | - | $ 1.41 B | ||
|
Iterum Therapeutics
ITRM
|
-18.7 M | - | - | $ 591 K | ||
|
Virpax Pharmaceuticals
VRPX
|
-12.1 M | - | -45.12 % | $ 2.85 M | ||
|
Navidea Biopharmaceuticals
NAVB
|
-14.1 M | - | -2.99 % | $ 2.47 M | ||
|
Stealth BioTherapeutics Corp
MITO
|
-46.3 M | - | - | $ 23.9 M | ||
|
OncoSec Medical Incorporated
ONCS
|
-37 M | - | 31.87 % | $ 1.61 M | ||
|
BioDelivery Sciences International
BDSI
|
37.1 M | - | -4.8 % | $ 255 M | ||
|
Albireo Pharma
ALBO
|
-123 M | - | -0.23 % | $ 916 M | ||
|
bluebird bio
BLUE
|
-270 M | - | - | $ 546 M | ||
|
Landos Biopharma
LABP
|
-22.7 M | - | 0.58 % | $ 144 M | ||
|
CASI Pharmaceuticals
CASI
|
-34 M | - | - | $ 35.4 M | ||
|
ContraFect Corporation
CFRX
|
-64.6 M | - | -5.16 % | $ 5.39 M | ||
|
Sigilon Therapeutics
SGTX
|
-43.7 M | - | - | $ 728 M | ||
|
Regulus Therapeutics
RGLS
|
-50 M | - | - | $ 155 M | ||
|
NGM Biopharmaceuticals
NGM
|
-151 M | - | - | $ 127 M | ||
|
Aravive
ARAV
|
-70.8 M | - | -13.39 % | $ 1.45 M | ||
|
Checkmate Pharmaceuticals
CMPI
|
-61.5 M | - | - | $ 231 M | ||
|
Crinetics Pharmaceuticals
CRNX
|
-517 M | $ 84.95 | 0.13 % | $ 7.99 B |